Combining microfocused ultrasound with botulinum toxin and temporary and semi-permanent dermal fillers

Safety and current use

Sabrina G. Fabi, Mitchel P. Goldman, Daniel C. Mills, W. Philip Werschler, Jeremy B. Green, Joely Kaufman, Robert A. Weiss, Carl S. Hornfeldt

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background A microfocused ultrasound system with visualization (MFU-V) is currently indicated for use as a noninvasive dermatological aesthetic treatment to lift the eyebrows, lax submental and neck tissue, and improve lines and wrinkles of the dé ecollet é. OBJECTIVE To determine the existence of any safety signals when combining MFU-V with botulinum toxin-A and/or semipermanent and temporary dermal fillers. MATERIALS AND METHODS A retrospective chart review was performed using subjects who received aesthetic treatments including incobotulinumtoxinA injection, cohesive polydensified matrix hyaluronic acid (CPM HA) dermal fillers, and calcium hydroxylapatite (CaHA) dermal fillers within 6 months of treatment with MFU-V in the same or different anatomic areas. RESULTS All subjects (N = 101; 96 female; 25-70 year old) received MFU-V, 18% received incobotulinumtoxinA injections, and 81% were treated with CPM HA and/or CaHA fillers. Seven adverse events (7%) were reported: bruising/purpura (n = 4), swelling (n = 1), paresthesia (n = 1), and herpes simplex virus (HSV) outbreak (n = 1). Only the HSV outbreak was considered to be related to combined treatments. CONCLUSION Although limited by relatively few subjects, the results of the present study suggest that the safety profile of MFU-V combined with other aesthetic products is consistent with the safety profiles of the individual treatments.

Original languageEnglish (US)
Pages (from-to)S168-S176
JournalDermatologic Surgery
Volume42
DOIs
StatePublished - May 15 2016
Externally publishedYes

Fingerprint

Botulinum Toxins
Safety
Esthetics
Hyaluronic Acid
Durapatite
Disease Outbreaks
Calcium
Eyebrows
Therapeutics
Type A Botulinum Toxins
Injections
Purpura
Paresthesia
Human Herpesvirus 1
Simplexvirus
Neck
Dermal Fillers

ASJC Scopus subject areas

  • Dermatology
  • Surgery

Cite this

Fabi, S. G., Goldman, M. P., Mills, D. C., Philip Werschler, W., Green, J. B., Kaufman, J., ... Hornfeldt, C. S. (2016). Combining microfocused ultrasound with botulinum toxin and temporary and semi-permanent dermal fillers: Safety and current use. Dermatologic Surgery, 42, S168-S176. https://doi.org/10.1097/DSS.0000000000000751

Combining microfocused ultrasound with botulinum toxin and temporary and semi-permanent dermal fillers : Safety and current use. / Fabi, Sabrina G.; Goldman, Mitchel P.; Mills, Daniel C.; Philip Werschler, W.; Green, Jeremy B.; Kaufman, Joely; Weiss, Robert A.; Hornfeldt, Carl S.

In: Dermatologic Surgery, Vol. 42, 15.05.2016, p. S168-S176.

Research output: Contribution to journalArticle

Fabi, SG, Goldman, MP, Mills, DC, Philip Werschler, W, Green, JB, Kaufman, J, Weiss, RA & Hornfeldt, CS 2016, 'Combining microfocused ultrasound with botulinum toxin and temporary and semi-permanent dermal fillers: Safety and current use', Dermatologic Surgery, vol. 42, pp. S168-S176. https://doi.org/10.1097/DSS.0000000000000751
Fabi, Sabrina G. ; Goldman, Mitchel P. ; Mills, Daniel C. ; Philip Werschler, W. ; Green, Jeremy B. ; Kaufman, Joely ; Weiss, Robert A. ; Hornfeldt, Carl S. / Combining microfocused ultrasound with botulinum toxin and temporary and semi-permanent dermal fillers : Safety and current use. In: Dermatologic Surgery. 2016 ; Vol. 42. pp. S168-S176.
@article{22c65f610dc14f46a576e7ed583add52,
title = "Combining microfocused ultrasound with botulinum toxin and temporary and semi-permanent dermal fillers: Safety and current use",
abstract = "Background A microfocused ultrasound system with visualization (MFU-V) is currently indicated for use as a noninvasive dermatological aesthetic treatment to lift the eyebrows, lax submental and neck tissue, and improve lines and wrinkles of the d{\'e} ecollet {\'e}. OBJECTIVE To determine the existence of any safety signals when combining MFU-V with botulinum toxin-A and/or semipermanent and temporary dermal fillers. MATERIALS AND METHODS A retrospective chart review was performed using subjects who received aesthetic treatments including incobotulinumtoxinA injection, cohesive polydensified matrix hyaluronic acid (CPM HA) dermal fillers, and calcium hydroxylapatite (CaHA) dermal fillers within 6 months of treatment with MFU-V in the same or different anatomic areas. RESULTS All subjects (N = 101; 96 female; 25-70 year old) received MFU-V, 18{\%} received incobotulinumtoxinA injections, and 81{\%} were treated with CPM HA and/or CaHA fillers. Seven adverse events (7{\%}) were reported: bruising/purpura (n = 4), swelling (n = 1), paresthesia (n = 1), and herpes simplex virus (HSV) outbreak (n = 1). Only the HSV outbreak was considered to be related to combined treatments. CONCLUSION Although limited by relatively few subjects, the results of the present study suggest that the safety profile of MFU-V combined with other aesthetic products is consistent with the safety profiles of the individual treatments.",
author = "Fabi, {Sabrina G.} and Goldman, {Mitchel P.} and Mills, {Daniel C.} and {Philip Werschler}, W. and Green, {Jeremy B.} and Joely Kaufman and Weiss, {Robert A.} and Hornfeldt, {Carl S.}",
year = "2016",
month = "5",
day = "15",
doi = "10.1097/DSS.0000000000000751",
language = "English (US)",
volume = "42",
pages = "S168--S176",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Combining microfocused ultrasound with botulinum toxin and temporary and semi-permanent dermal fillers

T2 - Safety and current use

AU - Fabi, Sabrina G.

AU - Goldman, Mitchel P.

AU - Mills, Daniel C.

AU - Philip Werschler, W.

AU - Green, Jeremy B.

AU - Kaufman, Joely

AU - Weiss, Robert A.

AU - Hornfeldt, Carl S.

PY - 2016/5/15

Y1 - 2016/5/15

N2 - Background A microfocused ultrasound system with visualization (MFU-V) is currently indicated for use as a noninvasive dermatological aesthetic treatment to lift the eyebrows, lax submental and neck tissue, and improve lines and wrinkles of the dé ecollet é. OBJECTIVE To determine the existence of any safety signals when combining MFU-V with botulinum toxin-A and/or semipermanent and temporary dermal fillers. MATERIALS AND METHODS A retrospective chart review was performed using subjects who received aesthetic treatments including incobotulinumtoxinA injection, cohesive polydensified matrix hyaluronic acid (CPM HA) dermal fillers, and calcium hydroxylapatite (CaHA) dermal fillers within 6 months of treatment with MFU-V in the same or different anatomic areas. RESULTS All subjects (N = 101; 96 female; 25-70 year old) received MFU-V, 18% received incobotulinumtoxinA injections, and 81% were treated with CPM HA and/or CaHA fillers. Seven adverse events (7%) were reported: bruising/purpura (n = 4), swelling (n = 1), paresthesia (n = 1), and herpes simplex virus (HSV) outbreak (n = 1). Only the HSV outbreak was considered to be related to combined treatments. CONCLUSION Although limited by relatively few subjects, the results of the present study suggest that the safety profile of MFU-V combined with other aesthetic products is consistent with the safety profiles of the individual treatments.

AB - Background A microfocused ultrasound system with visualization (MFU-V) is currently indicated for use as a noninvasive dermatological aesthetic treatment to lift the eyebrows, lax submental and neck tissue, and improve lines and wrinkles of the dé ecollet é. OBJECTIVE To determine the existence of any safety signals when combining MFU-V with botulinum toxin-A and/or semipermanent and temporary dermal fillers. MATERIALS AND METHODS A retrospective chart review was performed using subjects who received aesthetic treatments including incobotulinumtoxinA injection, cohesive polydensified matrix hyaluronic acid (CPM HA) dermal fillers, and calcium hydroxylapatite (CaHA) dermal fillers within 6 months of treatment with MFU-V in the same or different anatomic areas. RESULTS All subjects (N = 101; 96 female; 25-70 year old) received MFU-V, 18% received incobotulinumtoxinA injections, and 81% were treated with CPM HA and/or CaHA fillers. Seven adverse events (7%) were reported: bruising/purpura (n = 4), swelling (n = 1), paresthesia (n = 1), and herpes simplex virus (HSV) outbreak (n = 1). Only the HSV outbreak was considered to be related to combined treatments. CONCLUSION Although limited by relatively few subjects, the results of the present study suggest that the safety profile of MFU-V combined with other aesthetic products is consistent with the safety profiles of the individual treatments.

UR - http://www.scopus.com/inward/record.url?scp=84969530924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969530924&partnerID=8YFLogxK

U2 - 10.1097/DSS.0000000000000751

DO - 10.1097/DSS.0000000000000751

M3 - Article

VL - 42

SP - S168-S176

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

ER -